News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

John Wayne Cancer Institute Researchers Identify Epigenomic Test That Could Improve Treatment for Specific Gastric Cancers


12/11/2007 11:10:31 PM

SANTA MONICA, Calif.--(BUSINESS WIRE)--A study by researchers at the John Wayne Cancer Institute at Saint John’s Health Center in a recent issue of Journal of Clinical Oncology identifies activation of the enzyme COX-2 in gastric cancer tumors as a prognostic indicator for poor outcome. The study suggests that inhibiting COX-2 with readily available drugs may improve outcomes for some gastric cancer patients.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES